Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline

Praveen Vikas, Hans Messersmith, Carolyn Compton, Lynette Sholl, Russell R. Broaddus, Anjee Davis, Maria Estevez-Diz, Rohan Garje, Panagiotis A. Konstantinopoulos, Aliza Leiser, Anne M. Mills, Barbara Norquist, Michael J. Overman, Davendra Sohal, Richard C. Turkington, Tyler Johnson

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

PURPOSEThe College of American Pathologists (CAP) has developed a guideline on testing for mismatch repair (MMR) and microsatellite instability (MSI) for patients considered for immune checkpoint inhibitor therapy. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations.METHODSThe CAP guideline was reviewed for developmental rigor by methodologists. An ASCO Endorsement Panel subsequently reviewed the content and the recommendations.RESULTSThe ASCO Endorsement Panel determined that the recommendations from the CAP guideline, published on August 3, 2022, are clear, thorough, and based on the most relevant scientific evidence. ASCO endorses Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer.RECOMMENDATIONSWithin the guideline, MMR immunohistochemistry (IHC), MSI polymerase chain reaction, and MSI next-generation sequencing are all recommended testing options for colorectal cancer, MMR-IHC and MSI-polymerase chain reaction for gastroesophageal and small bowel cancer, and only MMR-IHC for endometrial cancer. No recommendation in favor of any testing method over another could be made for any other cancer. Tumor mutational burden was not recommended as a surrogate for DNA MMR deficiency. If MMR deficiency consistent with Lynch syndrome is detected, it should be communicated to the treating physician.Additional information is available at www.asco.org/molecular-testing-and-biomarkers-guidelines.

Original languageEnglish (US)
Pages (from-to)1943-1948
Number of pages6
JournalJournal of Clinical Oncology
Volume41
Issue number10
DOIs
StatePublished - Apr 1 2023
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline'. Together they form a unique fingerprint.

Cite this